细胞周期蛋白依赖激酶6
乳腺癌
体内
化学
激酶
癌症研究
药理学
帕博西利布
不利影响
体外
癌症
联合疗法
治疗效果
临床试验
酶抑制剂
细胞生长
结构-活动关系
化疗
BRD4
医学
IC50型
癌细胞
肿瘤科
离体
内科学
细胞周期蛋白依赖激酶
作者
Long Zheng,Yiwei Zheng,Sijie Wu,Yonglei Zhang,Zhongwen Luo,Yuhan Jiang,Shunxin Guo,Meiting Zou,Lingyi Kong,Xiaobing Wang
标识
DOI:10.1021/acs.jmedchem.5c03487
摘要
The clinical application of CDK4/6 inhibitors is constrained by their narrow indications. To improve therapeutic efficacy against breast cancer, combination therapies using CDK4/6 inhibitors with BET inhibitors are being explored in clinical trials. Our study demonstrates that the CDK4/6 inhibitor Abemaciclib and the BRD4 inhibitor BQ0 exert a synergistic effect in inhibiting the proliferation of triple-negative breast cancer (TNBC) cells in vitro. Based on these findings, we designed and synthesized a series of dual-target inhibitors that simultaneously target CDK6 and BRD4. Among the newly synthesized compounds, 7f and 7f15 exhibited potent inhibitory activity against both CDK6 and BRD4, along with remarkable antiproliferative activity on TNBC cells. In vivo studies using the MDA-MB-231 xenograft mouse model revealed that 7f15 exhibits robust antitumor activity without significant adverse effects. The kinases selectivity experimental suggested that 7f15 is a pan-BET inhibitor. In summary, 7f15, hereby designated as KWZL-7f15, is a novel dual CDK6/BET inhibitor with promising therapeutic potential for the treatment of triple-negative breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI